Fluidigm Stock News

Fluidigm Corp (NASDAQ: FLDM) expects Q4 FY21 sales of $38.0 million - $38.3 million, exceeding the company's prior guidance of $31 million – $34 million and the analyst estimate of $32.7 million.

Digital PCR (dPCR) is a straightforward and reproducible strategy that doesn''t depend on an alignment bend for test target evaluation. It permits exact, profoundly touchy evaluation of nucleic acids. Furthermore, it is utilized for outright evaluation and examination of minority

Fluidigm Corporation (NASDAQ:FLDM) price on Friday, December 10, rose 1.68% above its previous days close as an upside momentum from buyers pushed the stocks value to $4.24. A look at the stocks price movement, the close in the last trading session was $4.17, moving within a range at $4.095 and $4.33. The beta value (5-Year Major Improvements In Fluidigm Corporation (FLDM) Stock Need To Be Considered Read More »

No Published Viral Mutations to Date, Including Omicron Variant, Meaningfully Impact the Regions of the Viral Genome Targeted by the Assay No Published Viral Mutations to Date, Including Omicron Varia

Olink Holding AB (publ) (NASDAQ:OLK) and Fluidigm (NASDAQ:FLDM) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends. Profitability This table compares Olink Holding AB (publ) and Fluidigms net margins, return on equity []

Fluidigm Corporation (NASDAQ:FLDM) concluded the trading at $4.29 on Friday, December 03 with a fall of -2.72% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $4.41 and 5Y monthly beta was reading 1.58 with its price kept floating in the range Analysts Provide Insight On How High Fluidigm Corporation (FLDM) Can Go Read More »

A biochip is a collection of miniaturized test sites (microarrays) arranged on a solid substrate that permits many tests to be performed at the same time in order to achieve higher throughput and speed. Biochip Technology Market is estimated to

Fluidigm (NASDAQ:FLDM) and Olink Holding AB (publ) (NASDAQ:OLK) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, risk and profitability. Insider & Institutional Ownership 75.6% of Fluidigm shares are held by institutional investors. Comparatively, 17.0% []

After a hot start, the stock has recently lagged the market. Is now a good time to buy?

Data Bridge Market research presents the top quality and comprehensive COVID-19 Saliva Screening Test Potential research report which provides clear insights into market dynamics and prospects the whole market including global production, revenue forecast, value and volume. This COVID-19

The COVID-19 Saliva Screening Test Market research report presents a top-notch analysis that incorporates market restaurants, drivers, and opportunities available in the market. The report also segments the market by how a competitive environment is developed among leading players across

Related Stocks: RMBL , PLUG , FLDM , GLHA , ARRW , NOTV , DNZ , KIN , VIAC , AFAQ , GGPI ,

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will participate in investor meetings and present updates regarding Fluidigms business strategy and financial performance at the following investor event:

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive healt